Back to top
more

Integra LifeSciences (IART)

(Real Time Quote from BATS)

$31.35 USD

31.35
596,475

-0.07 (-0.22%)

Updated Jul 25, 2024 09:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Artivion (AORT) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 30.77% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Accuray (ARAY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Integra (IART) Could Beat Earnings Estimates Again

by Zacks Equity Research

Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope

by Zacks Equity Research

With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.

Why Is Abiomed (ABMD) Up 1.2% Since Last Earnings Report?

by Zacks Equity Research

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Integra's (IART) Q3 Earnings Top, Gross Margin Declines

by Zacks Equity Research

Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.

Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 19.44% and 1.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Investors Should Retain Integra (IART) Stock for Now

by Zacks Equity Research

Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.

Penumbra (PEN) Surges 6.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Penumbra (PEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut

by Zacks Equity Research

Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 2.50% and 0.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Artivion (AORT) Soars 10.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Artivion (AORT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Investors Should Retain Integra (IART) Stock for Now

by Zacks Equity Research

Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.

Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Integra (IART) Gains From Innovation Amid Cost Constraints

by Zacks Equity Research

Integra's (IART) international sales in CSS grow led by the strong performance of CereLink in Europe and growth in Asia.